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Pulmonary hypertension (PH) is a disease of various origins. Nitric oxide—a potent
vasodilator—is a key player of pulmonary vasoregulation. Nitric oxide signaling is mainly
mediated by the guanylate cyclase/cyclic guanylate monophosphate pathway. The effects of
this second messenger system are limited by enzymatic degradation through phosphodies-
terases (PDEs). Recently, beneficial effects of the oral PDE-5 inhibitor sildenafil (originally
approved for the treatment of erectile dysfunction) were reported for the treatment of PH.
We provide a brief overview of the experimental and clinical application of PDE inhibitors
in the field of PH. In particular, studies reporting the clinical effectiveness of sildenafil are
highlighted. This agent, despite oral application, displays characteristics of a pulmonary
selective vasodilator. In addition, evidence shows that sildenafil is operative mainly in the
vasculature of well-ventilated areas of the lung. However, to date, controlled randomized
trials proving the efficacy of this approach for the treatment of pulmonary arterial hyperten-
sion are lacking. The results of such studies have to confirm the current encouraging findings
before recommendations regarding the use of PDE-5 inhibitors as a new treatment for PH
can be made. (J Am Coll Cardiol 2004;43:68S–72S) © 2004 by the American College of
Cardiology Foundationt
N
h
I
a
i
p
s
v
s
C
P
C
l
s
v
(
i
s
i
T
a
i
R
m
s
Aitric oxide (NO) is constitutively produced in the lung by
O synthases. The main cellular sources of lung NO
roduction are the vascular endothelium and the airway
pithelia (1,2). Local NO production regulates pulmonary
erfusion depending on alveolar ventilation to assure opti-
ized ventilation/perfusion distribution (3,4). Nitric oxide
ynthase activity is regulated on transcriptional and post-
ranslational redox-based modulation level (5). The com-
on signaling pathway of endogenous vasodilators, such as
O, prostaglandins, and natriuretic peptides, engage cyclic
ucleotides (cyclic adenylate monophosphate [cAMP] and
yclic guanylate monophosphate [cGMP]) (Fig. 1). These
econd messengers are mainly produced by activation of
denylate-cyclase and guanylate-cyclase (GC) (6). Phos-
hodiesterases (PDEs) represent a superfamily of enzymes,
ith PDE-1 through PDE-11 being currently known, that
nactivate cAMP and cGMP, with different tissue distribu-
ion and substrate specificities (6,7). Owing to the stabili-
ation of these second messengers, PDE inhibitors differ-
ntially regulate levels of cAMP and/or cGMP, depending
n their selectivity profile. Therefore, they might offer as
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O-related vascular effects. The efficacy of this approach
as been proven in several experimental studies (8,9).
nterestingly, the major cGMP-degrading PDE, PDE-5, is
bundantly expressed in lung tissue (7). The orally admin-
stered selective PDE-5 inhibitor sildenafil has been ap-
roved for the treatment of erectile dysfunction (10). De-
pite the broad use in healthy men and in patients with a
ariety of underlying diseases, sildenafil displays an excellent
afety profile (11).
URRENT TREATMENTS FOR
ULMONARY ARTERIAL HYPERTENSION (PAH)
ontinuous infusion of prostacyclin has been shown to be a
ife-saving therapy in severe primary pulmonary hyperten-
ion (PPH) (12) and to improve exercise capacity in collagen
ascular disease-associated pulmonary hypertension (PH)
13). There are, however, drawbacks of this therapy, includ-
ng substantial systemic side effects due to lack of pulmonary
electivity of the prostanoid, the need of progressive dosage
ncrease, and septic complications of the intravenous line.
o preserve the advantageous effects of prostacyclin, and
void several of these side effects, the concept of aerosolized
loprost for treatment of PAH was developed (14,15).
ecently, the results of a double-blind, placebo-controlled
ulticenter study demonstrated that daily inhaled iloprost
ignificantly improved exercise capacity, New York Heart
ssociation (NYHA) functional classification, dyspneacoring, and event-free survival over a three-month obser-
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hronic thromboembolic PH (16).
Another promising approach to medical treatment of
AH is the use of the nonselective oral endothelin receptor
ntagonist bosentan. In a controlled phase III study, bosen-
an showed beneficial effects on exercise tolerance in pa-
ients with PPH and those with PH associated with
ollagen vascular disease (17). However, liver toxicity was
ocumented in a minor percentage of patients, and long-
erm experience will have to elucidate the occurrence of this
omplication during chronic treatment of a substantial
umber of patients.
The search continues for an “ideal” pulmonary vasodilator
hat combines pulmonary selectivity with simplicity of
dministration and reduced side effects. Recently, the
igure 2. Comparison of pulmonary vasodilative potency of oral sildenafil,
as performed in 30 patients with precapillary pulmonary hypertension. In
as compared with that of sildenafil, inhaled iloprost, or a combination o
low dose of sildenafil (12.5 mg), while in the upper right figure a comb
he effects of 50 mg sildenafil compared to NO and iloprost, and the lower r
Abbreviations and Acronyms
cAMP  cyclic adenylate monophosphate
cGMP  cyclic guanylate monophosphate
GC  guanylate cyclase
HIV  human immunodeficiency virus
NO  nitric oxide
NYHA  New York Heart Association
PAH  pulmonary arterial hypertension
PDE  phosphodiesterase
PH  pulmonary hypertension
PPH  primary pulmonary hypertensionadapted from Ghofrani et al., Ann Intern Med 2002;136:515–22).igure 1. Scheme of nitric oxide (NO) metabolism pathway. In this
iagram the nitric oxide (NO) pathway is depicted. In presence of oxygen
O2) and/or alveolar ventilation, NO synthases (NOS) are activated and
roduce NO from L-arginine via L-citrulline. The NO activates soluble-
nd membrane-bound guanylate cyclases, which synthesize cyclic guanylate
onophosphate (cGMP), which subsequently activates cGMP-kinase.
his enzyme—by activation of K-channels and subsequent Ca-
hannel inhibition—evokes a reduction of intracellular Ca concentra-
ion, finally resulting in vasodilation. The downstream effects of NO areinhaled nitric oxide (NO), and inhaled iloprost. Comparative vasodilator testing
each group, the effect of inhaled NO on pulmonary vascular resistance (PVR)
f both. In the upper left figure, inhaled NO and iloprost were compared with
ination of sildenafil and iloprost was tested. The lower left figure summarizes
ight figure shows the data of a combination of high-dose sildenafil with iloprost
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NO and PDE Inhibitors in Pulmonary Hypertension June 16, 2004:68S–72SDE-5 inhibitor sildenafil has come into the focus of
nvestigation.
ILDENAFIL IN EXPERIMENTAL PH
n animal experiments, several PDE inhibitors displayed
avorable pulmonary vasodilatory potential (8,18,19). Sil-
enafil in such a setting proved to be a potent and
ulmonary-selective vasodilator (9). Most interestingly, this
gent was also able to reduce hypoxia-induced PH in man
nd in an experimental animal model (20). The effects of
ildenafil on chronic remodeling processes in the pulmonary
igure 3. Hemodynamic and gas-exchange response to inhaled nitric ox
ulmonary hypertension. Deviations from preintervention baseline are displ
O  cardiac output; mPAP  mean pulmonary arterial pressure; mSAP
changes in mm Hg); PVRI  pulmonary vascular resistance index; PVR
hofrani et al., Lancet 2002;360:895–900).asculature are not yet well known. It is hoped that future iesults derived from long-term experimental models of PH
ill provide insight into these mechanisms.
LINICAL EXPERIENCE WITH
ILDENAFIL FOR THE TREATMENT OF CHRONIC PH
he vasodilatory effects of NO administered by inhalation
re restricted to the pulmonary vasculature. Nitric oxide has
very short half-life, is used as a screening agent for lung
asoreactivity (21), and is effective for improving gas ex-
hange in selected patients with the adult respiratory dis-
ress syndrome (22). Weaning from chronic NO treatment
O), infused PGI2, and oral sildenafil in patients with lung fibrosis and
for inhaled NO, infused prostacyclin (PGI iv), and oral sildenafil (Sil oral).
ean systemic arterial pressure; PaO2  partial pressure of arterial oxygen
ratio  ratio of pulmonary to systemic vascular resistance (adapted fromide (N
ayed
 m
/SVRn patients with the adult respiratory distress syndrome was
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ith PAH, short-term application of sildenafil during right
eart catheterization showed the potential to reduce pulmo-
ary vascular resistance in a dose-dependent manner. Inter-
stingly, the vasodilatory effects were mainly operative in the
ulmonary circulation and were significantly stronger than
he effects seen with inhaled NO (24). In combination with
nother pulmonary selective vasodilator, inhaled iloprost,
ugmentation of the pulmonary vasodilatory effect of each
ingle agent was noted (24,25) (Fig. 2). In patients with
eteriorating severe PAH despite ongoing prostanoid treat-
ent, long-term adjunct oral sildenafil improved exercise
apacity and pulmonary hemodynamics (26). The combina-
ion of prostanoids and sildenafil could prove to be an
ppealing concept for future treatment of PH. Numerous
eports about the clinical use of sildenafil in PAH as
hort-term application and long-term treatment in uncon-
rolled trials have been published (24,27–34).
Interestingly, sildenafil also appears to be effective for treat-
ng patients with PH of origin other than PPH. In patients
uffering from human immunodeficiency virus (HIV)-related
H, sildenafil was similarly effective in reducing pulmonary
ascular resistance as in PPH (35). Moreover, this therapeutic
pproach has been reported to be effective in pediatric patients
36). In the presence of interstitial lung disease, systemic
dministration of vasodilators regularly increases the blood
ow to low or nonventilated lung areas by interfering with the
hysiological hypoxic vasoconstrictor mechanism, thereby
orsening preexistent ventilation/perfusion mismatch and
hunt flow. The decrease in arterial oxygenation and the
asting of the small ventilatory reserve of these patients are the
egative consequences of this effect. Most interestingly, oral
ildenafil was found to cause pulmonary vasodilation in pa-
ients with lung fibrosis and PH, with the overall vasodilatory
otency corresponding to that of intravenous prostacyclin.
otably, in contrast to the infused prostanoid, selectivity for
ell-ventilated lung areas was demonstrated for sildenafil,
esulting in an improvement rather than deterioration of gas
xchange (37) (Fig. 3). Also, recent data suggest beneficial
ong-term effectiveness in patients with nonoperable chronic
hromboembolic PH (38). The importance of this finding is
he fact that there are few therapeutic options that can be
ffered to these patients (except lung transplantation).
onclusions. The NO/cGMP axis represents a pivotal
ignaling pathway for the lung circulation. Phosphodiester-
ses, as regulators of the second messenger response to
ndogenous NO, are thus of great therapeutic potential for
he treatment of lung circulatory disorders. Among the
linically available PDE inhibitors, sildenafil is a most
romising agent for pulmonary vasodilation and long-term
ntiremodeling in the lung vasculature of PAH patients.
lthough orally administered, sildenafil does possess fea-
ures of pulmonary selectivity. It may be favorably combined
ith other vasodilative and antiproliferative agents. Large
rials, including a placebo-controlled phase III trial with
ildenafil in patients with PAH, are currently underway.eprint requests and correspondence: Dr. Hossein-Ardeschir
hofrani, Department of Internal Medicine, Pulmonary Hyper-
ension Center, University Hospital, Klinikstrasse 36, 35392 Gies-
en, Germany. E-mail: ardeschir.ghofrani@innere.med.uni-
iessen.de.
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